AB054. The role of urine ErbB3 protein in early diagnosis and prognosis evaluation of renal cell carcinoma

© Translational Andrology and Urology. All rights reserved. Transl Androl Urol, 2017;6(S3) tau.amegroups.com amount of 125I, reaction time, pH, and reaction volume on the labeling rate of the 125I-RSOAds-hTERT/PSA oncolytic adenovirus marker were measured. Radioactive oncolytic adenoviruses were isolated and purified by column chromatography; the radiochemical purities of the 125I-RSOAds-hTERT/PSA marker at different times were detected by paper chromatography. After the addition of radioactive iodine-labeled prostate cancer-specific oncolytic adenoviruses to prostate cancer cells, changes in the inhibitory rate were measured by methylthiazolyldiphenyltetrazolium bromide (MTT) assays. Results: The radiochemical purity of the 125I-RSOAdshTERT/PSA marker was >95%, and the marker was stable (93–94%) after storage at 4 °C for 7 days. The optimal conditions were 0.5 μL of 125I (about 0.2 mCi, 7.4 MBq), 25 μg of NBS, 100 μL of 8×10 viral protein (VP)/ mL 125I-RSOAds-hTERT/PSA virus solution, 3 min of reaction time, pH 7.5, and 120 μL PBS. Radioactive iodinelabeled prostate cancer-specific oncolytic adenoviruses inhibited the proliferation of prostate cancer cells significantly. Conclusions: Radioactive 125I labeling of the hTERT/PSA dual-regulated prostate cancer-specific oncolytic adenovirus is feasible, and the radiochemical purity of the marker was stable under defined conditions. Radioactive iodine-labeled prostate cancer-specific replication-selective oncolytic adenoviruses significantly inhibited prostate cell growth.